Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celtaxsys To Hash Out Phase III Cystic Fibrosis Endpoints With US FDA

Executive Summary

Private start-up's acebilustat failed to improve lung function in Phase II, but the anti-inflammatory showed large numerical reductions in pulmonary exacerbations, which can be fatal.

Advertisement

Related Content

Vertex Cystic Fibrosis Forecast Brightens, With Gloomy Prospects For Competition
Vertex Looks To Triple Combos For CF After Doublet Success
Orkambi Efficacy Sways FDA Panel Despite Uncertainty Over Lumacaftor’s Role

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel